Abbvie Inc

NYSE:ABBV   4:00:00 PM EDT
+0.71 (+0.45%)
7:47:32 PM EDT: $159.16 +0.91 (+0.58%)
Products, Regulatory

Rinvoq Achieved Superiority Versus Dupixent For Primary And All Ranked Secondary Endpoints In Phase 3B

Published: 12/10/2020 16:10 GMT
Abbvie Inc (ABBV) - Rinvoq™ (upadacitinib) Achieved Superiority Versus Dupixent® (dupilumab) for Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-head Study in Adults With Atopic Dermatitis.
Abbvie Inc - 71 Percent of Patients Treated With Upadacitinib Achieved Primary Endpoint of Easi 75.
Abbvie Inc - Safety Profile of Upadacitinib Was Consistent With Previous Atopic Dermatitis Studies, With No New Safety Risks Observed.
Abbvie Inc - One Treatment-emergent Death Due to Bronchopneumonia Associated With Influenza a Occurred in a Patient Who Received Upadacitinib.
Abbvie Inc - No Major Adverse Cardiac Events Or Venous Thromboembolic Events Were Reported in Either Treatment Group.